Yukinori Ozaki, Medical Doctor at Cancer Institute Hospital of JFCR, shared a post on X:
“An ongoing phase III trial addressing unmet clinical needs Abemaciclib for locoregional recurrence of HR+HER2- breast cancer (JCOG2313, AURA trial, NCT07190443).”
Title: Randomized Phase III Trial for Evaluating the Efficacy of Adjuvant Abemaciclib in Patients With Locoregional Recurrence of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: JCOG2313, AURA Trial
Authors: Yukinori Ozaki, Noriko Mitome, Emi Tokuda, Shinsuke Sasada, Akihiko Shimomura, Keita Sasaki, Riku Kajikawa, Chikako Funasaka, Atsushi Yoshida, Shin Takayama, Toshiyuki Ishiba, Takehiko Sakai, Yasuaki Sagara, Hideo Shigematsu, Kazuki Sudo, Kaori Terata, Yoichi Naito, Tomomi Fujisawa, Shigehira Saji, Hiroji Iwata, Fumikata Hara, Tadahiko Shien
Read the Full Article.
HER2 Heterogeneity in Breast Cancer May Explain Why Some Tumors Escape T-DXd
